Mounjaro and Zepbound: The Case for Two Hormones at Once
Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024

Search
60 stories for“ageing in place”
Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024

Berberine lowers cholesterol and blood sugar in small trials, but comparing it to semaglutide misreads both the data and the biology.
Feb 14, 2024

Semaglutide hits one receptor and tirzepatide hits two. The third one retatrutide adds is glucagon, which does the opposite of what a diabetes drug is supposed to do. It is also where the liver results and the safety questions both come from.
Aug 20, 2026

Coeliac blood tests look for antibodies your body only makes while you are eating gluten. Cut it out first and the result can come back clear while the disease carries on.
Jul 16, 2026

TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.
Aug 11, 2026

An engineered gum reduced HPV and nearly eliminated two bacteria linked to head and neck cancer. It is early work, and the delivery method is the genuinely clever part.
Aug 6, 2026

A tiny implant paired with camera glasses can return useful central vision to some people with advanced macular degeneration, and Europe has cleared its sale.
Jul 23, 2026

WHO’s new figures show real progress despite a billion more vehicles, while poorer countries and vulnerable road users remain on the wrong side of the decline.
Jul 22, 2026

FDA approval of the first oral PCSK9 inhibitor adds a once-daily option for adults who need greater LDL reduction, but it does not replace individualized cardiovascular care.
Aug 1, 2026

Peptide is a chemical category, not a claim. The two versions most people actually buy are the ones with the least regulation and, oddly, the best safety record. Here is what the trials support and what physics gets in the way of.
Aug 20, 2026

Trial data on stopping semaglutide shows most of the lost weight comes back within a year. Here is what the STEP 1 extension found.
May 15, 2024

Semaglutide now has a heart disease approval too. Here is what the STEP and SELECT trial data really says, and what it does not.
Mar 13, 2024

Diabetic retinopathy does not hurt, does not blur vision early, and gives no warning a person can feel. By the time sight changes, the damage that caused it has usually been accumulating for years.
Jul 19, 2026

Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026

Lilly does not expect to file for approval until the first quarter of 2027. Search the drug's name today and you can have a vial by the weekend. The gap between those two facts is where the harm happens.
Aug 20, 2026
